David E. Lazar - 26 Jul 2023 Form 4 Insider Report for TITAN PHARMACEUTICALS INC (TTNP)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: TTNP
Reported as of: 26 Jul 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Jul 2023, 19:39:50 UTC
Prior SEC filing: 28 Jun 2023
Next SEC filing: 04 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ David E. Lazar

Key filing fact

David E. Lazar filed Form 4 for TITAN PHARMACEUTICALS INC (TTNP) on 31 Jul 2023.

Key facts

This page summarizes David E. Lazar's Form 4 filing for TITAN PHARMACEUTICALS INC (TTNP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Jul 2023, 19:39.

Change

Previous filing in this sequence was filed on 28 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TTNP transaction

Common Stock

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 26 Jul 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.